Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen 

Plus: Cytokinetics gains on takeout talk and updates from Lilly-Fauna, Sanofi, Illumina, BioMarin, MeiraGTx and more

BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design

As R&D head John Reed departs for a new gig at J&J, Sanofi remains in the midst of a transition

As deal with Seagen brings local rights to first-in-class ADC, COO Smiley is looking ahead to a broader set of opportunities

Roche to pay $250M for Good Therapeutics’ PD-1-regulated IL-2 program, leaving new company Bonum Therapeutics to develop the platform

BioCentury’s roundup of translational news

Company expanding pivotal trial as it assesses next indications

The French pharma lays out its strategy for re-entering oncology, bolstered by new Sarclisa data

The targets and indications CAR T developers are exploring to get to efficacy in solid tumors